Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Open access
Kerdidani, Dimitra, Aerakis, Emmanouil, Verrou, Kleio-Maria, Angelidis, Ilias, Douka, Katerina, Maniou, Maria-Anna, Stamoulis, Petros, Goudevenou, Katerina, Prados, Alejandro, Tzaferis, Christos, Ntafis, Vasileios, Vamvakaris, Ioannis, Kaniaris, Evangelos, Vachlas, Konstantinos, Sepsas, Evangelos, Koutsopoulos, Anastasios, Potaris, Konstantinos, Tsoumakidou, Maria · 2022 · Journal of Experimental Medicine

Abstract

A key unknown of the functional space in tumor immunity is whether CD4 T cells depend on intratumoral MHCII cancer antigen recognition. MHCII-expressing, antigen-presenting cancer-associated fibroblasts (apCAFs) have been found in breast and pancreatic tumors and are considered to be immunosuppressive. This analysis shows that antigen-presenting fibroblasts are frequent in human lung non-small cell carcinomas, where they seem to actively promote rather than suppress MHCII immunity. Lung apCAFs directly activated the TCRs of effector CD4 T cells and at the same time produced C1q, which acted on T cell C1qbp to rescue them from apoptosis. Fibroblast-specific MHCII or C1q deletion impaired CD4 T cell immunity and accelerated tumor growth, while inducing C1qbp in adoptively transferred CD4 T cells expanded their numbers and reduced tumors. Collectively, we have characterized in the lungs a subset of antigen-presenting fibroblasts with tumor-suppressive properties and propose that cancer immunotherapies might be strongly dependent on in situ MHCII antigen presentation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20210815

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 196

Metadata

Authors
Kerdidani, D., Aerakis, E., Verrou, K.-M., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., Ntafis, V., Vamvakaris, I., Kaniaris, E., Vachlas, K., Sepsas, E., Koutsopoulos, A., Potaris, K., & Tsoumakidou, M.
Venue
Journal of Experimental Medicine
Published
2022-01-14
Volume
219
Issue
2
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W4206489510
Cited by
196
References
23
FWCI
7.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. https://app.cochat.ai/papers/10.1084/jem.20210815
The paper
Kerdidani, D., Aerakis, E., Verrou, K.-M., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., Ntafis, V., Vamvakaris, I., Kaniaris, E., Vachlas, K., Sepsas, E., Koutsopoulos, A., Potaris, K., & Tsoumakidou, M. (2022). Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20210815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.